Association of a DNA Damage Response Deficiency (DDRD) Assay with Prognosis in Resected Esophageal and Gastric Adenocarcinoma
Download the following Poster Presentation: Association of a DNA Damage Response Deficiency (DDRD) Assay with Prognosis in Resected Esophageal and Gastric Adenocarcinoma.
Conclusions:
The DDRD assay:
1. Is the first gene expression biomarker to utilise FFPE tissue in oesophago-gastric cancer.
2. Demonstrates a strong association with prognosis in:
EAC patients treated with neo-adjuvant chemotherapy
GC patients treated with surgery + adjuvant chemo/chemoXRT
3. Predicts Pathological Response to neo-adjuvant chemotherapy
4. Could personalise treatment approaches in oesophago-gastric cancer.